Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

For emerging biotech companies, the race to IND is no longer defined by speed alone. | Lonza explains why early de-risking ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...